Se prevé que el mercado de la esteatohepatitis no alcohólica (NASH) alcance los 24.266,81 millones de dólares en 2028, desde los 1.631,92 millones de dólares de 2021; se espera que registre una tasa compuesta anual del 47,1 % entre 2021 y 2028.
En la enfermedad del hígado graso no alcohólico (NAFLD), la grasa se acumula en el hígado. El hígado graso no alcohólico (NAFL) y la esteatohepatitis no alcohólica (NASH) son tipos de NAFLD. Cuando la acumulación de grasa causa inflamación y daño, conduce al desarrollo de NASH, que puede provocar cicatrices en el hígado. La cicatrización del hígado es una afección potencialmente mortal llamada cirrosis.
El informe ofrece información y un análisis en profundidad del mercado de la esteatohepatitis no alcohólica (NASH) enfatizando varios parámetros, como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado. También proporciona un análisis del panorama competitivo de los principales actores del mercado en todo el mundo. Además, incluye el impacto de la pandemia de COVID-19 en el mercado en todas las regiones. La pandemia de COVID-19 ha alterado las condiciones socioeconómicas de varios países del mundo. En América del Norte, Estados Unidos se vio profundamente afectado por la pandemia de COVID-19. La lesión hepática en forma de aumento de las transaminasas e hiperbilirrubinemia entre los pacientes con COVID-19 se puede atribuir a un par de factores, incluida la enfermedad hepática preexistente. La comorbilidad de la enfermedad del hígado graso no alcohólico (NAFLD) y NASH en estos pacientes los hace propensos a sufrir formas graves de lesión hepática. Dada la alta prevalencia de NAFLD en todo el mundo, es fundamental reconocer los efectos de la COVID-19 en dichos pacientes, que incluyen el papel de las comorbilidades, la progresión de la enfermedad y la gravedad de la COVID. La presencia de fibrosis en lugar de NASH/NAFLD se asocia con peores resultados clínicos y mayor mortalidad en pacientes con COVID-19.
El impacto de COVID-19 en poblaciones de pacientes comórbidos , incluidas las personas con diabetes, obesidad, enfermedad del hígado graso y NASH, ha desencadenado la necesidad de brindar una atención óptima a los pacientes. El Global Liver Institute se compromete a trabajar con investigadores e innovadores de todo el mundo para evaluar e informar rápidamente una respuesta sólida a esta pandemia. Las investigaciones que giran en torno a la lucha contra NAFLD y NASH indican que la relación prevista con el problema de peso es marcada. Por tanto, una alta incidencia de EHNA exige diagnósticos y tratamientos avanzados, lo que impulsa la investigación y el desarrollo en el mercado. Por lo tanto, la crisis de COVID-19 ha impulsado el crecimiento del mercado de esteatohepatitis no alcohólica (NASH).
Perspectivas estratégicas
regiones lucrativas para el mercado de esteatohepatitis no alcohólica (NASH)
Perspectivas del mercado
El aumento de las iniciativas para aumentar la conciencia sobre la NASH impulsa el crecimiento del mercado
La NASH es una afección poco reconocida. Para una vía de derivación estructurada y una detección temprana, es esencial generar una mayor conciencia sobre esta enfermedad entre el público en general y los médicos de atención primaria (PCP). Al establecer una vía clara para las derivaciones de pacientes y campañas de concientización para los pacientes, se puede identificar a más personas y enviarlas a especialistas para una evaluación adicional. Para crear conciencia sobre NASH, el Programa de Educación sobre NASH lanzó la campaña de educación pública el 12 de junio de 2018, que se celebra como el "Día Internacional de NASH", para crear conciencia sobre NAFLD y su forma más avanzada, NASH, que afecta a más de ~115 millones. personas.
NASH 24X7, una plataforma digital destinada a aumentar la exposición y la concientización sobre la epidemia de NASH, tomó algunas medidas en el Día Internacional de NASH 2019 a través del apoyo de los profesionales sanitarios y la concientización de los pacientes. y programas de comunicados de prensa/TV. Para crear conciencia en este día, NASH Crusaders de NASH 24X7 se unió a los principales proveedores de atención médica (HCP, por sus siglas en inglés), especialmente gastroenterólogos y hepatólogos, en toda la India para realizar muchas actividades de concientización y atención a pequeña y gran escala. talleres educativos sobre la salud del hígado, destacando la necesidad de un estilo de vida saludable para prevenir NAFLD/NASH.
En el Día Internacional de NASH 2020, la American Liver Foundation se unió a una comunidad global para crear conciencia sobre NASH con el apoyo de la Fundación Allergan. American Liver Foundation (ALF) ahora está poniendo a prueba un programa de mensajes de texto NASH, en el que las personas pueden registrarse para recibir 3 mensajes semanales durante 10 semanas. Los mensajes constan de hipervínculos a recursos de NASH, hechos relevantes, cuestionarios interactivos y sugerencias sensatas para la autogestión diaria. La ALF abrirá este sistema al público en general cuando el piloto esté terminado y evaluado. Colaboró con el Global Liver Institute (GLI) en el Día Internacional de NASH y compartió algunas publicaciones en las redes sociales vinculadas a publicaciones de GLI y la página del Día Internacional de NASH.
Así , las crecientes iniciativas para impulsar la concientización sobre NASH están impulsando el mercado de la esteatohepatitis no alcohólica (NASH).
Información basada en productos
Basada En cuanto al producto, el mercado de la esteatohepatitis no alcohólica (NASH) se segmenta en vitamina E y pioglitazona, ocaliva, elafibranor, selonsertib y otros. cenicriviroc y otros. En 2021, el segmento de otros ocupó la mayor cuota de mercado. El selonsertib & Se espera que el segmento cenicriviroc registre la CAGR más rápida del 73,3% durante el período previsto.
Mercado de soluciones de preservación de órganos, por producto: 2020 y 2028
Información basada en aplicaciones
Según la aplicación, el mercado de la esteatohepatitis no alcohólica (NASH) se divide en tratamiento y diagnóstico. En 2021, el segmento de tratamiento ocupó una mayor participación del mercado. Sin embargo, se espera que el segmento de tratamiento registre una CAGR mayor del 47,3% durante el período de pronóstico.
Información basada en el canal de ventas
Basado en canal de ventas, el mercado de esteatohepatitis no alcohólica (NASH) se segmenta en farmacia hospitalaria, farmacia minorista y proveedor en línea. En 2021, el segmento de farmacia minorista tuvo la mayor participación del mercado. Además, se espera que el segmento de farmacias minoristas registre la tasa compuesta anual más alta del 47,2 % durante 2021-2028.
Los actores del mercado de esteatohepatitis no alcohólica (NASH) adoptan estrategias orgánicas como el lanzamiento y la expansión de productos para ampliar su presencia y cartera de productos en todo el mundo, así como para satisfacer las crecientes demandas.
Por geografía
Basado en En cuanto a la geografía, el mercado de la esteatohepatitis no alcohólica (NASH) está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y resto de Europa), Asia Pacífico (China, Japón). , India, Australia, Corea del Sur y resto de Asia Pacífico), Oriente Medio y Asia. África (Emiratos Árabes Unidos, Arabia Saudita, Sudáfrica y resto de Medio Oriente y África) y Sur y África. Centroamérica (Brasil, Argentina y resto de Centro y Suramérica).
Perfiles de Empresas
- Genfit SA
- One Way Liver, SL
- BioPredictive SAS
- Cadila Pharmaceuticals Ltd.
- Laboratorios Prometheus
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.
The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.
The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.
The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.
The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.
The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.
Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.
North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.
The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.
- Genfit SA
- One Way Liver, S.L.
- BioPredictive S.A.S
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)